BrightGene Bio-Medical Technology Co., a Chinese biopharmaceutical company, has received RMB550 million (US$80.06 million) in a pre-IPO round of financing, led by Sequoia China and HighLight Capital, with participation from GF Qianhe Investment, according to a WeChat announcement released today.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?